Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

<< Previous

Bullboard Posts

Next >>

Post by scarlet1967on Feb 09, 2022 9:48am

177 Views

Post# 34411934

UQAM

UQAM put a reference related TH1902 on their website recently. Although we are waiting for the oncology results THTX posting on LinkedIn about cancer and now this by UQAM are encouraging.

“The Chair in Cancer Prevention and Treatment, directed by Professor Borhane Annabi of the Department of Chemistry, is associated with the preclinical development of TH1902, a chemotherapy targeting Sortilin-positive cancers, in partnership with Theratechnologies and the Canadian Cancer Society.”

https://chimie.uqam.ca/babillard/nouvelles/developpement-preclinique-du-th1902/

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing